Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Symetis gets CHF23mm through its Series B round

Executive Summary

Symetis SA, which is developing the Acurate self-positioning device for percutaneous aortic valve replacement, has raised CHF23mm ($21.3mm) through its Series B venture round. Vinci Capital & Renaissance and Wellington Partners led the financing and were joined by fellow first-time investor Banexi Venture Partners and current shareholders Aravis Venture, BioMedInvest, Novartis Venture Funds, Truffle Capital, and individual backers. Symetis will use some of the funds to start in vivo preclinical testing of its Acurate TF transfemoral device.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies